Financings in Brief: Haemonetics
This article was originally published in The Gray Sheet
Executive Summary
Haemonetics: Board authorizes the repurchase, "at prevailing prices as market conditions warrant," of 1 mil. shares of common stock. The Braintree, Massachusetts-based manufacturer of blood processing systems currently has 28 mil. shares outstanding. Haemonetics recently completed a repurchase program, also of 1 mil. shares, announced last year ("The Gray Sheet" May 9, 1994, p. 35)...